CANbridge Acquires China Rights to Apogenix Brain Cancer Treatment

CANbridge Life Sciences of Beijing in-licensed China rights to a clinical-stage anti-TNF drug candidate from Apogenix, a German biopharma, as a treatment for glioblastoma multiforme in China, Macao and Hong Kong. CANbridge will also have an option for other indications. The drug, APG101, is a fully-human fusion protein designed to inhibit the CD95 ligand and restore the immune response against tumors. Apogenix will receive upfront and milestone payments, plus royalties at tiered, double-digit rates on China revenues. More details.... Share this with colleagues: // //